← Back to Search

Pentraxin

PRM-151 for Idiopathic Pulmonary Fibrosis (STARSCAPE-OLE Trial)

Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until study completion (up tp 4 years)
Awards & highlights

STARSCAPE-OLE Trial Summary

This trial will study the effects of an experimental drug called PRM-151 on people with a lung disease called idiopathic pulmonary fibrosis.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

STARSCAPE-OLE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until study completion (up tp 4 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline until study completion (up tp 4 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Targeted Clinical Laboratory Test Results
Percentage of Participants with Adverse Events (AE)
Percentage of Participants with Infusion Related Reactions (IRRs) and other AEs of Special Interest
+1 more
Secondary outcome measures
Annual Rate of Change in 6-Minute Walk Distance (6MWD)
Annual Rate of Change in Carbon Monoxide Diffusing Capacity (DLCO)
Annual Rate of Change in FVC% Predicted
+8 more

STARSCAPE-OLE Trial Design

1Treatment groups
Experimental Treatment
Group I: PRM-151Experimental Treatment1 Intervention
Corhort A: Participants entering, following participation in study PRM-151-202. Cohort B: Participants entering, following participation in study WA42293.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRM-151 (Zinpentraxin Alfa)
2021
Completed Phase 3
~670

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,428 Previous Clinical Trials
1,088,937 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,442 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Clinical TrialsStudy DirectorHoffmann-La Roche
2,199 Previous Clinical Trials
888,385 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,677 Patients Enrolled for Idiopathic Pulmonary Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has PRM-151 acquired regulatory approval from the FDA?

"PRM-151's safety has been corroborated by multiple clinical trials, and it thus received a score of 3."

Answered by AI

If a patient is interested, how many different hospitals offer this particular treatment?

"To limit participant burden, it is best to choose a clinical trial site near you from the 69 locations. Santa Barbara, Birmingham and San Diego are a few of the many options."

Answered by AI

Is this the first time PRM-151 has been investigated?

"As of now, PRM-151 has 2 ongoing studies in Phase 3. Additionally, there are a wealth of clinical trial sites for PRM-151 with 871 different locations."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
1

What questions have other patients asked about this trial?

Will I have to be at the clinic or is this remote?
PatientReceived no prior treatments

Why did patients apply to this trial?

Recently diagnosed with IPF and looking for other medications.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
2021. "A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04594707.
~33 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top